These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26179060)

  • 1. Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology.
    Laplane L; Beke A; Vainchenker W; Solary E
    Stem Cells; 2015 Oct; 33(10):2887-92. PubMed ID: 26179060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status in cancer cell reprogramming and its clinical implications.
    Izgi K; Canatan H; Iskender B
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy.
    Vicente-Dueñas C; Hauer J; Ruiz-Roca L; Ingenhag D; Rodríguez-Meira A; Auer F; Borkhardt A; Sánchez-García I
    Semin Cancer Biol; 2015 Jun; 32():3-9. PubMed ID: 24530939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
    Semi K; Yamada Y
    Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mammalian DNA methylation and its roles during the induced re-programming of somatic cells].
    Hongwei S; Tiezhu A; Shanhua P; Chunsheng W
    Yi Chuan; 2014 May; 36(5):431-8. PubMed ID: 24846992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The genetic safety of induced pluripotent stem (iPS) cells].
    Chen Q; Shi QH
    Yi Chuan; 2012 Mar; 34(3):260-8. PubMed ID: 22425944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cells: a new approach for physiological research.
    Pfannkuche K; Hannes T; Khalil M; Noghabi MS; Morshedi A; Hescheler J; Dröge P
    Cell Physiol Biochem; 2010; 26(2):105-24. PubMed ID: 20798495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo.
    Ohnishi K; Semi K; Yamada Y
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):10-5. PubMed ID: 25019993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells.
    Mosca E; Cocola C; Sabour D; Pelucchi P; Bertalot G; Palumbo O; Carella M; Götte M; Schöler HR; Reinbold R; Zucchi I; Milanesi L
    In Silico Biol; 2010; 10(5-6):207-21. PubMed ID: 22430355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Pluripotent Stem Cells from Cancer-Resistant Naked Mole-Rats.
    Miura K; Oiwa Y; Kawamura Y
    Adv Exp Med Biol; 2021; 1319():329-339. PubMed ID: 34424523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?
    de Lázaro I; Yilmazer A; Kostarelos K
    J Control Release; 2014 Jul; 185():37-44. PubMed ID: 24746625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
    Matsuda Y; Semi K; Yamada Y
    Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging methods for preparing iPS cells.
    Miyazaki S; Yamamoto H; Miyoshi N; Takahashi H; Suzuki Y; Haraguchi N; Ishii H; Doki Y; Mori M
    Jpn J Clin Oncol; 2012 Sep; 42(9):773-9. PubMed ID: 22826352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of somatic and pluripotent cells reveals novel pathways involved in reprogramming.
    Cai YN; Dai XH; Zhang QH; Hu R; Dai ZM
    Genet Mol Res; 2015 Oct; 14(4):12085-92. PubMed ID: 26505355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular barriers to processes of genetic reprogramming and cell transformation.
    Chestkov IV; Khomyakova EA; Vasilieva EA; Lagarkova MA; Kiselev SL
    Biochemistry (Mosc); 2014 Dec; 79(12):1297-307. PubMed ID: 25716723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular reprogramming and cancer development.
    Semi K; Matsuda Y; Ohnishi K; Yamada Y
    Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic cells with a heavy mitochondrial DNA mutational load render induced pluripotent stem cells with distinct differentiation defects.
    Wahlestedt M; Ameur A; Moraghebi R; Norddahl GL; Sten G; Woods NB; Bryder D
    Stem Cells; 2014 May; 32(5):1173-82. PubMed ID: 24446123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53: guardian of reprogramming.
    Menendez S; Camus S; Izpisua Belmonte JC
    Cell Cycle; 2010 Oct; 9(19):3887-91. PubMed ID: 20948296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation.
    Chen T; Yuan D; Wei B; Jiang J; Kang J; Ling K; Gu Y; Li J; Xiao L; Pei G
    Stem Cells; 2010 Aug; 28(8):1315-25. PubMed ID: 20521328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cells: from derivation to application in biochemical and biomedical research.
    Novosadova EV; Grivennikov IA
    Biochemistry (Mosc); 2014 Dec; 79(13):1425-41. PubMed ID: 25749158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.